Cannovex

Cannovex

Foundation date

06/08/2016

Sector

#Biotechnology - other

Subsector

• #R&D Services - Screening
• #Other - AgBio

Therapeutic areas

• #Digestive system
• #Diseases of the blood and blood-forming organs - immune disorders
• #Diseases of the eye
• #Diseases of the nervous system
• #Endocrine - nutritional and metabolic diseases
• #Mental and behavioural disorders
• #Musculoskeletal system and connective tissue
• #Neoplasms / cancer / oncology
• #Respiratory system
• #Skin and subcutaneous tissue

Cannovex is a Benelux-origin biotech company which develops cannabinoid-based medicines to improve the lives of patients worldwide. Over a two year period, Cannovex has conducted an in-depth and exhaustive study of medical literature on this subject, and continues to monitor all scientific publications. These efforts establish Cannovex as the designated conversation partner, sounding board and source of information on cannabinoid medicines for all stakeholders.

Based on the insights resulting from the above-mentioned research, Cannovex is now planning the development of cannabinoid-based medicines in specific therapeutic areas and for well-defined indications. Cannovex aims to set up clinical studies, in collaboration with EU university hospitals, to provide proofs of concept (PoC). Based on these PoCs, Cannovex will explore partnerships with pharmaceutical companies to conduct end-stage clinical trials, to apply for market authorisation with European Medicines Agency (EMA) and similar authorities, and to bring our cannabinoid medicinal products to the markets worldwide.